HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for

First Page		Document Content
Date: 2015-11-10 11:42:30 Chemistry Clinical medicine Organic chemistry MEK inhibitor Protein kinase inhibitors B-Raf inhibitor Sulfonamides Vemurafenib Cobimetinib Keratoacanthoma Ofloxacin		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 719,43 KB Share Document on Facebook

	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for DocID: 1pQS7 - View Document
	SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Vemurafenib, Abiraterone, Enzalutamide) Part 1 - Patient Information DocID: 1gjh0 - View Document
	Machine Reading for Cancer Panomics Hoifung Poon 1 DocID: 1fQeq - View Document
	490 NEDERLANDS TIJDSCHRIFT VOOR DERMATOLOGIE EN VENEREOLOGIE \| VOLUME 23 \| NUMMER 08 \| september 2013 Spiny folliculaire hyperkeratose door vemurafenib, een BRAF‑remmer DocID: 1epqH - View Document
	Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent DocID: 1bnwn - View Document